Professional Documents
Culture Documents
The mean clinical status rank score was not significantly different at 24 weeks between placebo
(95.8) and sildenafil (94.2) (P=.85). Changes in 6-minute walk distance at 24 weeks in patients who
received placebo (15.0 m [IQR, 26.0 to 45.0]) or sildenafil (5.0 m [IQR,37.0 to 55.0]; P=.92) were
also not significantly different. Adverse events occurred in 78 placebo patients (76%) and 90
sildenafil patients (80%). Serious adverse events occurred in 16 placebo patients (16%) and 25
sildenafil patients (22%).